#Latest news with #BySaveHims&HersHealthIncBloomberg24-02-2025BusinessBloombergHims 2025 Sales Outlook Beats Despite Weight-Loss UncertaintyThe company's quarterly sales also beat expectations Hims' reliance on compounded Ozempic faces increasing scrutiny By Save Hims & Hers Health Inc. provided 2025 sales guidance that exceeded Wall Street projections even as the company's copycat weight-loss drug business faces an unclear future. Revenue for the year will be $2.3 billion to $2.4 billion, Hims said on Monday afternoon, above analysts' estimates of $2.09 billion.
Bloomberg24-02-2025BusinessBloombergHims 2025 Sales Outlook Beats Despite Weight-Loss UncertaintyThe company's quarterly sales also beat expectations Hims' reliance on compounded Ozempic faces increasing scrutiny By Save Hims & Hers Health Inc. provided 2025 sales guidance that exceeded Wall Street projections even as the company's copycat weight-loss drug business faces an unclear future. Revenue for the year will be $2.3 billion to $2.4 billion, Hims said on Monday afternoon, above analysts' estimates of $2.09 billion.
24-02-2025
